FitLife Brands Announces Third Quarter 2025 Results

Rhea-AI Summary

FitLife Brands (NASDAQ: FTLF) reported third-quarter 2025 revenue of $23.5 million, a 47% increase year‑over‑year following the August 8, 2025 acquisition of substantially all assets of Irwin Naturals (Irwin), whose results from Aug 9–Sep 30 are included.

Wholesale revenue rose to $13.2 million (56% of sales), up 156% YoY, while online revenue was $10.3 million, down 5% YoY. Gross margin was 37.2% (38.9% excluding Irwin inventory step‑up amortization). Net income was $0.9 million ($0.10 basic EPS), down from $2.1 million, driven by acquisition transaction costs, lower margins, and higher tax expense. Adjusted EBITDA was $3.8 million (+6% YoY) and TTM adjusted EBITDA was $13.6 million.

Positive

• Total revenue +47% YoY to $23.5M
• Wholesale revenue +156% YoY to $13.2M
• Adjusted EBITDA +6% YoY to $3.8M (TTM $13.6M)
• Irwin contributed $6.8M of the $7.5M revenue increase

Negative

• Gross margin down 660 bps to 37.2% (vs 43.8%)
• Net income declined from $2.1M to $0.9M
• Online revenue down 5% YoY to $10.3M
• Increased costs: acquisition transaction expense and rising whey protein costs

Insights

Senior Financial Analyst

Revenue grew 47% driven by the Irwin acquisition, but margins and net income fell; results are mixed for near-term profitability.

Consolidated revenue rose to $23.5 million, a 47% increase year‑over‑year, with Irwin contributing approximately $6.8 million of the $7.5 million increase and wholesale rising to $13.2 million (56% of revenue). Adjusted EBITDA increased to $3.8 million (up 6%), while net income declined to $0.9 million and basic EPS fell to $0.10, driven by acquisition transaction costs, lower gross margin and higher tax expense.

Key operational details: consolidated gross margin fell to 37.2% (or 38.9% excluding the inventory step‑up amortization), Legacy FitLife showed modest organic strength excluding MRC, MusclePharm delivered 55% revenue growth but at compressed margins due to rising whey costs, and Irwin produced a wholesale‑heavy 32.2% gross margin for the partial period (or 37.9% excluding step‑up amortization). Management cited supply chain and SG&A savings at Irwin, first Amazon sale on October 11, 2025 and current Amazon run‑rate of about $10,000 per day.

Dependencies and risks are explicit: margin recovery depends on absorbing or passing through rising protein costs and realizing stated Irwin cost and supply‑chain efficiencies; short‑term net income will remain sensitive to acquisition‑related charges and promotional investments. Watch over the next two quarters for: 1) the impact of planned Irwin cost cuts and Amazon rollout on margin and wholesale mix; 2) MusclePharm gross margin trends or announced price changes to offset whey cost pressure; and 3) stability in MRC following the lapping of Dr. Tobias declines in early 2026. Time horizon for these indicators is near term (Q4 2025 and early 2026), with integration metrics observable over the next ~12 months.

OMAHA, NE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the third quarter ended September 30, 2025.

Highlights for the third quarter ended September 30, 2025 include:

• On August 8, 2025, the Company completed the acquisition of substantially all of the assets of Irwin Naturals (“Irwin”), and Irwin’s operating results for the period of August 9 through September 30 are included in FitLife’s consolidated financials for the third quarter of 2025.
• Total revenue was $23.5 million, an increase of 47% compared to the third quarter of 2024.  
• Wholesale revenue was $13.2 million, representing 56% of revenue and an increase of 156% compared to the third quarter of 2024.
• Excluding the amortization of the inventory step-up related to the Irwin acquisition, gross margin was 38.9% compared to 43.8% during the third quarter of 2024.
• Net income was $0.9 million compared to $2.1 million during the third quarter of 2024, with the decline driven primarily by transaction expense associated with acquisition of Irwin, lower gross margin, and higher income tax expense.
• Basic earnings per share and diluted earnings per share were $0.10 and $0.09, respectively, compared to $0.23 and $0.21 during the third quarter of 2024.
• Adjusted EBITDA was $3.8 million, a 6% increase compared to the third quarter of 2024.
  
  

For the third quarter ended September 30, 2025, total revenue was $23.5 million, an increase of 47% compared to $16.0 million during the same period last year. Revenue from Irwin accounted for $6.8 million of the $7.5 million increase.  

Wholesale revenue for the quarter was $13.2 million, an increase of 156% compared to the third quarter of 2024. Excluding the $6.5 million of wholesale revenue contributed by Irwin, wholesale revenue for the Company’s other brands increased 30% compared to the third quarter of 2024, with wholesale revenue for Legacy FitLife (excluding MRC), MRC, and MusclePharm increasing 3%, 20%, and 112% respectively. Wholesale revenue accounted for 56% and 32% of the Company’s total revenue during the quarters ended September 30, 2025 and 2024, respectively.

Online revenue for the quarter was $10.3 million, a decrease of 5% compared to the third quarter of 2024. Excluding the $0.3 million of online revenue contributed by Irwin, online revenue for the Company’s other brands declined 8% compared to the third quarter of 2024. Online revenue for Legacy FitLife (excluding MRC) increased by 14% during the quarter, while MRC declined by 16% and MusclePharm declined by 3%. Online revenue accounted for 44% and 68% of the Company’s total revenue during the quarters ended September 30, 2025 and 2024, respectively.

Gross margin for the quarter ended September 30, 2025, was 37.2% compared to 43.8% during the same period in the prior year. Excluding the amortization of the inventory step-up related to the Irwin acquisition, gross margin was 38.9% for the third quarter of 2025.

Net income for the third quarter of 2025 was $0.9 million compared to $2.1 million during the quarter ended September 30, 2024. Basic and diluted earnings per share were $0.10 and $0.09, respectively, compared to $0.23 and $0.21 during the third quarter of 2024.   The decline in net income and earnings per share is primarily due to transaction expense associated with the Irwin acquisition, lower gross margin, and increased income tax expense.

Adjusted EBITDA for the quarter ended September 30, 2025, was $3.8 million, a 6% increase compared to the same period in 2024. Adjusted EBITDA for the trailing twelve months, which includes less than eight weeks of Irwin’s results, was $13.6 million.

Performance of Acquired Brands

One of the primary metrics used by management to evaluate the performance of the Company’s brands is contribution, a non-GAAP financial measure which management defines as gross profit less advertising and marketing expenditures.   Other companies may also report contribution as a performance metric, but their definition or calculation of contribution may differ from the Company’s. Management believes that contribution, as defined by the Company, is a particularly relevant performance metric since it incorporates the gross profit associated with a specific brand or collection of brands as well as the advertising and marketing expenditures associated with the same brand or brands. With limited exception, other operating expense incurred by the Company is generally not allocable to a specific brand or collection of brands.

Management intends to provide this level of disclosure for acquired brands for approximately two years following a transaction, after which the performance of acquired brands will be reported as part of Legacy FitLife results. Other than for MusclePharm, the numbers in the contribution tables presented below in the body of the press release represent the performance of a collection of brands. Legacy FitLife consists of twelve brands, and Irwin consists of three brands. These collections of brands do not meet the definition of operating segments and are not managed as such.

Legacy FitLife
(Unaudited)	2024					2025
	Q3		Q4			Q1		Q2		Q3
Wholesale revenue	3,930		3,250			4,648		4,385		4,076
Online revenue	9,582		8,944			9,325		9,187		8,779
Total revenue	13,512		12,194			13,973		13,572		12,855
Gross profit	6,125		5,465			6,284		6,116		5,788
Gross margin	45.3	%	44.8	%		45.0	%	45.1	%	45.0	%
Advertising and marketing	999		862			879		953		1,135
Contribution	5,126		4,603			5,405		5,163		4,653
Contribution as a % of revenue	37.9	%	37.7	%		38.7	%	38.0	%	36.2	%

For the third quarter of 2025, Legacy FitLife revenue declined 5% compared to the same period last year, driven by an 8% decrease in online revenue due to a drop in traffic to MRC product listing pages, partially offset by a 4% increase in wholesale revenue. Excluding MRC, Legacy FitLife wholesale revenue increased 3%, online revenue increased 14%, and total revenue increased 8% in the third quarter of 2025 compared to the same quarter last year.

Gross profit and contribution decreased by 6% and 9%, respectively, for Legacy FitLife. Gross margin decreased slightly from 45.3% during the third quarter of 2024 to 45.0% during the third quarter of 2025. Contribution as a percentage of revenue decreased from 37.9% to 36.2% over the same time period. Excluding MRC, Legacy FitLife gross margin increased from 42.6% during the third quarter of 2024 to 45.7% during the third quarter of 2025, and contribution as a percentage of revenue increased from 41.5% to 43.1% over the same time period.

MusclePharm
(Unaudited)	2024					2025
	Q3		Q4			Q1		Q2		Q3
Wholesale revenue	1,231		1,689			658		1,311		2,610
Online revenue	1,234		1,130			1,305		1,244		1,199
Total revenue	2,465		2,819			1,963		2,555		3,809
Gross profit	876		747			590		788		754
Gross margin	35.5	%	26.5	%		30.1	%	30.8	%	19.8	%
Advertising and marketing	94		117			174		238		150
Contribution	782		630			416		550		604
Contribution as % of revenue	31.7	%	22.3	%		21.2	%	21.5	%	15.9	%

MusclePharm revenue increased 55% from the third quarter of 2024 to the third quarter of 2025, with wholesale revenue increasing 112%, partially offset by a 3% decrease in online revenue. As previously disclosed, in an effort to drive revenue growth, the Company is making targeted investments in advertising and promotion, primarily in the wholesale channel.  Beginning in the fourth quarter of 2024, the Company offered additional promotional incentives to certain wholesale partners in an effort to drive incremental growth for the MusclePharm brand.  The decrease in wholesale revenue that occurred during the first quarter was primarily due to one of our wholesale customers that took advantage of the Company’s promotional investment during the fourth quarter of 2024 without increasing their sell-through of the product, which affected their reorder volumes during the first quarter of 2025.

The Company anticipates that the increased promotional efforts will continue for the foreseeable future.  As a result of these investments, gross margin and contribution margin as a percent of revenue may fluctuate materially from quarter to quarter.

Gross margin and contribution as a percentage of revenue for MusclePharm were also adversely affected during the quarter by increasing whey protein costs. In an effort to gain market share, the Company has thus far absorbed these cost increases without raising prices to its customers. As protein costs continue to increase, the Company may implement price increases to offset at least a portion of the increased cost.

Irwin
(Unaudited)
	2025
	Q3
Wholesale revenue	6,510
Online revenue	311
Total revenue	6,821
Gross profit	2,194
Gross margin	32.2	%
Advertising and marketing	72
Contribution	2,122
Contribution as % of revenue	31.1	%

Irwin’s performance for the third quarter of 2025 includes the results of operations for the period from August 9 through September 30.  During this period, Irwin generated 95% of its revenue from the wholesale channel and 5% from online sales. Wholesale revenue during the quarter was adversely affected by approximately $0.6 million of sales that were pulled forward by the previous owner prior to closing the transaction. Online revenue during the third quarter of 2025 represents transactions through Irwin’s websites only. The Company did not begin selling Irwin products on Amazon until subsequent to the end of the third quarter.

Irwin generated gross margin of 32.2% and contribution as a percentage of revenue of 31.1% during the third quarter of 2025. Excluding amortization of the inventory step-up, Irwin’s gross margin and contribution as a percentage of revenue would have been 37.9% and 36.9%, respectively.  For comparison, Irwin’s gross margin prior to the acquisition by FitLife was 32.3% and 35.7% for 2024 and the first six months of 2025, respectively.

FitLife Consolidated
(Unaudited)	2024					2025
	Q3		Q4			Q1		Q2		Q3
Wholesale revenue	5,161		4,939			5,306		5,696		13,196
Online revenue	10,816		10,074			10,630		10,431		10,289
Total revenue	15,977		15,013			15,936		16,127		23,485
Gross profit	7,001		6,212			6,874		6,904		8,736
Gross margin	43.8	%	41.4	%		43.1	%	42.8	%	37.2	%
Advertising and marketing	1,093		979			1,053		1,191		1,357
Contribution	5,908		5,233			5,821		5,713		7,379
Contribution as % of revenue	37.0	%	34.9	%		36.5	%	35.4	%	31.4	%

For the Company overall, revenue increased 47%, gross profit increased 25%, and contribution increased 25% compared to the third quarter of 2024. Gross margin decreased to 37.2% compared to 43.8% during the third quarter of last year.   Contribution as a percentage of revenue decreased to 31.4% compared to 37.0% during the third quarter of last year. Excluding the inventory step-up of $0.4 million, gross margin and contribution as a percentage of revenue would have been 38.9% and 33.1%, respectively.

Management Commentary

Dayton Judd, the Company’s Chairman and CEO commented, “Although we are still working through the previously disclosed challenges associated with our MRC business, we are very encouraged by the performance of our other brands during the third quarter of 2025, with MusclePharm organic revenue increasing 55% and Legacy FitLife organic revenue excluding MRC increasing 8%. On a year-to-date basis, MusclePharm and Legacy FitLife excluding MRC have delivered organic revenue growth of 15% and 7%, respectively.

“We are pleased with the strong revenue performance of the MusclePharm brand, with wholesale revenue increasing 112% on a year-over-year basis during the quarter. This growth is a function of higher sales to existing customers as well as gaining new distribution. However, margins for this business were lower during the quarter, primarily due to increasing protein costs, which we are currently choosing to absorb as we continue to fight for increased distribution and sell-through. MusclePharm’s performance was consistent throughout the third quarter with revenue for each month higher than all previous months since we acquired the brand.

“Irwin is also off to a good start. As is the case with all acquisitions, there are a number of challenges that we are working through, but these challenges also represent opportunities for improved performance and we remain excited about the Irwin brands and their potential. Revenue for the third quarter was adversely affected by approximately $0.6 million of shipments that were pulled forward prior to the acquisition. In addition, since Irwin plans to become the primary seller of its products on Amazon, following the acquisition we ceased selling products to the wholesale partner who was the primary seller of Irwin products on Amazon. Prior to the acquisition, sales to this customer were approximately $0.5 million per quarter. 

“Our first sale of Irwin products on Amazon occurred on October 11, 2025. Since then, our sales on Amazon have increased consistently and are currently around $10,000 per day, or approximately $3.6 million on an annualized basis. At this point, Irwin is actively selling on only 116 of its 242 product listings. As other sellers run out of inventory, we expect to become the primary seller on all of our listings.

“In addition, we continue to work toward capturing supply chain and SG&A efficiencies at Irwin. Additional cost cuts were implemented during the third quarter that will impact the fourth quarter of 2025 and beyond. We are also working to rectify out-of-stock issues as well as increase the focus on new product development at Irwin.

“At MRC, we continue to work on initiatives designed to generate revenue off-Amazon as well as drive additional traffic to our listings on Amazon. Also, in early 2026, we will lap the initial revenue declines for the Dr. Tobias brand that began in February of 2025, so we are hopeful for greater stability for MRC in the near future.

“Our primary concerns right now relate to the increasing cost of whey protein, which primarily affects our MusclePharm brand, and general consumer weakness. Over the past couple of months, we have observed signs of increasing consumer weakness, which is validated by declining customer counts in brick-and-mortar retailers as well as consumer sentiment benchmarks being close to all-time lows. Although we remain optimistic about our brands and their long-term potential, these factors have an uncertain near-term effect.”

Earnings Conference Call

The Company will hold an investor conference call on Thursday, November 13, 2025 at 4:30 pm ET. Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 811541. International participants can dial (973) 528-0163 and provide the same code.

About FitLife Brands
FitLife Brands is a developer and marketer of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers. FitLife markets over 500 different products online and through various retail locations. FitLife is headquartered in Omaha, Nebraska. For more information, please visit our website at www.fitlifebrands.com.

Forward-Looking Statements
Statements in this release that are forward-looking involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to be materially different from any future performance that may be suggested in this news release. Such factors may include, but are not limited to, the ability of the Company to continue to grow revenue, the Company's ability to continue to achieve positive cash flow given the Company's existing and anticipated operating and other costs, and the Company’s ability to service its debt. Many of these risks and uncertainties are beyond the Company's control. Reference is made to the discussion of risk factors detailed in the Company's filings with the Securities and Exchange Commission including its reports on Form 10-K and Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.

FITLIFE BRANDS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)

		September 30, 2025				December 31, 2024
		(Unaudited)
ASSETS:
CURRENT ASSETS
Cash and cash equivalents		$	3,512			$	4,468
Restricted cash			-				52
Accounts receivable, net of allowance for credit losses of $22 and $41, respectively			9,640				1,626
Inventories, net of allowance for obsolescence of $254 and $100, respectively			22,227				11,074
Prepaid expense and other current assets			2,021				923
Total current assets			37,400				18,143
Property and equipment, net			135				75
Right of use asset			785				412
Intangibles, net of amortization of $275 and $152, respectively			51,648				26,235
Goodwill			19,366				13,022
Deferred tax asset			567				-
Other assets			83				644
TOTAL ASSETS		$	109,984			$	58,531
LIABILITIES AND STOCKHOLDERS' EQUITY:
CURRENT LIABILITIES:
Accounts payable		$	9,148			$	4,067
Accrued expense			6,803				684
Income taxes payable			1,688				1,415
Product returns			863				564
Term loan – current portion			8,094				4,500
Revolving line of credit			6,000				-
Lease liability – current portion			429				81
Total current liabilities			33,025				11,311
Term loan, net of current portion and unamortized deferred finance costs			32,363				8,550
Long-term lease liability, net of current portion			385				331
Derivative liability			32				-
Deferred tax liability			2,287				2,213
TOTAL LIABILITIES			68,092				22,405
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.01 par value, 10,000 shares authorized, none outstanding as of September 30, 2025 and December 31, 2024			-				-
Common stock, $0.01 par value, 120,000 shares authorized; 9,391 and 9,210 issued and outstanding as of September 30, 2025 and December 31, 2024			94				92
Additional paid-in capital			32,141				31,129
Retained earnings			10,253				5,567
Accumulated other comprehensive loss			(596	)			(662	)
TOTAL STOCKHOLDERS' EQUITY			41,892				36,126
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		$	109,984			$	58,531

FITLIFE BRANDS, INC. 
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(In thousands, except per share data)
(Unaudited)

		Three months ended September 30								Nine months ended September 30
		2025				2024				2025				2024
Revenue		$	23,485			$	15,977			$	55,548			$	49,456
Cost of goods sold			14,749				8,976				33,034				27,588
Gross profit			8,736				7,001				22,514				21,868
OPERATING EXPENSE:
Advertising and marketing			1,357				1,093				3,601				3,647
Selling, general and administrative			4,105				2,645				9,102				7,681
Merger and acquisition related			820				59				1,848				217
Depreciation and amortization			136				22				169				85
Total operating expense			6,418				3,819				14,720				11,630
OPERATING INCOME			2,318				3,182				7,794				10,238
OTHER EXPENSE (INCOME)
Interest income			(18	)			(19	)			(94	)			(41	)
Interest expense			580				326				1,049				1,085
Other expense			49				-				49				-
Foreign exchange gain			(43	)			(21	)			(57	)			(26	)
Total other expense			568				286				947				1,018
INCOME BEFORE INCOME TAX PROVISION			1,750				2,896				6,847				9,220
PROVISION FOR INCOME TAXES			829				770				2,161				2,306
NET INCOME		$	921			$	2,126			$	4,686			$	6,914
NET INCOME PER SHARE
Basic		$	0.10			$	0.23			$	0.50			$	0.75
Diluted		$	0.09			$	0.21			$	0.47			$	0.70
Basic weighted average common shares			9,391				9,196				9,332				9,196
Diluted weighted average common shares			9,997				9,930				9,962				9,886
COMPREHENSIVE INCOME:
NET INCOME		$	921			$	2,126			$	4,686			$	6,914
Foreign currency translation adjustment			(42	)			35				98				(136	)
Loss on derivatives			(32	)			-				(32	)			-
Comprehensive income		$	847			$	2,161			$	4,752			$	6,778

FITLIFE BRANDS, INC. 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(In thousands)
(Unaudited)

		Nine months ended September 30,
		2025				2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	4,686			$	6,914
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			169				85
Allowance for credit losses			(19	)			2
Allowance for inventory obsolescence			154				(76	)
Stock-based compensation			332				344
Amortization of deferred financing costs			31				31
Write-off of deferred financing costs			49				-
Amortization of inventory step-up			392				-
Changes in operating assets and liabilities:
Accounts receivable - trade			(680	)			18
Inventories			(860	)			(1,223	)
Deferred taxes			77				270
Prepaid expense and other current assets			(811	)			793
Right-of-use asset			139				72
Accounts payable			2,980				827
Income taxes payable			274				1,114
Lease liability			(114	)			(82	)
Accrued expense and other current liabilities			605				(434	)
Product returns			(209	)			(2	)
Net cash provided by operating activities			7,195				8,653
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash paid for Irwin acquisition			(42,500	)			-
Purchase of property and equipment			(37	)			(10	)
Net cash used in investing activities			(42,537	)			(10	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options			682				-
Borrowings on term loans			40,452				-
Payoff of 2023 term loans			(10,875	)			-
Payments on term loans			(2,250	)			(5,875	)
Borrowings on line of credit			6,000				-
Net cash provided by (used in) financing activities			34,009				(5,875	)
Foreign currency impact on cash			325				54
CHANGE IN CASH AND RESTRICTED CASH			(1,008	)			2,822
CASH AND RESTRICTED CASH, BEGINNING OF PERIOD			4,520				1,898
CASH AND RESTRICTED CASH, END OF PERIOD		$	3,512			$	4,720

Non-GAAP Financial Measures 
  
The financial information included in this release and the presentation below contain certain financial measures defined as “non-GAAP financial measures” by the SEC, including non-GAAP EBITDA and non-GAAP adjusted EBITDA. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. 
  
As presented below, non-GAAP EBITDA excludes interest, foreign currency gain/loss, income taxes, depreciation and amortization. Adjusted non-GAAP EBITDA excludes, in addition to interest, foreign currency gain/loss, taxes, depreciation and amortization, equity-based compensation, M&A/integration expense, restructuring and non-recurring gains or losses. The Company believes the non-GAAP measures provide useful information to both management and investors by excluding certain expense and other items that may not be indicative of its core operating results and business outlook. The Company believes that the inclusion of non-GAAP measures in the financial presentation below allows investors to compare the Company’s financial results with the Company’s historical financial results and is an important measure of the Company’s comparative financial performance. 

The Company’s calculation of Adjusted EBITDA for the three and nine months ended September 30, 2025 and 2024 is as follows:

		For the three months ended September 30,								For the nine months ended September 30,
		2025				2024				2025				2024
		(Unaudited)				(Unaudited)				(Unaudited)				(Unaudited)
Net income		$	921			$	2,126			$	4,686			$	6,914
Interest expense			580				326				1,049				1,085
Interest income			(18	)			(19	)			(94	)			(41	)
Foreign exchange gain			(43	)			(21	)			(57	)			(26	)
Provision for income taxes			829				770				2,161				2,306
Depreciation and amortization			136				22				169				85
EBITDA			2,405				3,204				7,914				10,323
Non-cash and non-recurring adjustments
Stock-based compensation			126				141				332				344
Merger and acquisition related			820				59				1,848				217
Amortization of inventory step-up			392				-				392				-
Writeoff of deferred financing costs			49				-				49				-
Restructuring costs			-				184				-				184
Adjusted EBITDA		$	3,792			$	3,588			$	10,535			$	11,068

investor@fitlifebrands.com

FAQ

What drove FitLife (FTLF) revenue growth in Q3 2025?

Revenue grew 47% YoY to $23.5M, largely due to the Irwin acquisition which added $6.8M in revenue.

How did FitLife's gross margin and EBITDA perform in Q3 2025 for FTLF?

Gross margin was 37.2% (38.9% excluding Irwin inventory step‑up amortization) and adjusted EBITDA was $3.8M.

Why did FitLife (FTLF) net income fall in Q3 2025?

Net income fell to $0.9M due to acquisition transaction expenses, lower gross margin and higher income tax expense.

How much wholesale growth did FitLife report for Q3 2025 (FTLF)?

Wholesale revenue increased 156% YoY to $13.2M, driven largely by Irwin and higher MusclePharm wholesale sales.

What impact did the Irwin acquisition have on FitLife's Q3 2025 results (FTLF)?

Irwin contributed $6.8M of the revenue increase, lowered consolidated gross margin due to inventory step‑up amortization, and shifted 95% of its Q3 revenue to wholesale.

What near‑term risks did FitLife (FTLF) highlight for investors?

Management cited rising whey protein costs affecting MusclePharm and general consumer weakness as near‑term concerns.